Newland Pharmaceutical Co., Ltd. (SHE:301277)

Market Cap	4.76B +17.5%
Revenue (ttm)	672.38M -7.4%
Net Income	121.25M -30.2%
EPS	0.31 -29.5%
Shares Out	392.08M
PE Ratio	39.13
Forward PE	n/a
Dividend	0.29 (2.28%)
Ex-Dividend Date	Apr 16, 2025

Volume	3,045,258
Average Volume	2,186,042
Open	12.18
Previous Close	12.13
Day's Range	11.79 - 12.32
52-Week Range	10.41 - 18.38
Beta	0.39
RSI	44.08
Earnings Date	Mar 20, 2026

About Newland Pharmaceutical

Newland Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical intermediates and APIs in China. It provides pharmaceutical intermediates, including L-4-hydroxyphenylglycine methyl ester, L-hydroxyphenylglycine potassium salt, L-4-hydroxyphenylglycine, and p-Toluenesulfonic acid. The company also offers APIs, such as ropivacaine hydrochloride, naphazoline hydrochloride, moxifloxacin hydrochloride, lidocaine hydrochloride, vildagliptin, tadalafil, chlorpheniramine maleate, clopidogrel bisulfate, l...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2005
• Employees: 1,042
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 301277

Financial Performance

In 2025, Newland Pharmaceutical's revenue was 672.38 million, a decrease of -7.44% compared to the previous year's 726.44 million. Earnings were 121.25 million, a decrease of -30.17%.